pharmaphorum April 24, 2024
Any new company wanting to make waves in applying artificial intelligence to drug discovery will need deep pockets and a top-tier science and management team – and startup Xaira Therapeutics has arrived at its launch party with both.
The San Francisco-based company has emerged from the incubators of ARCH Venture Partners and Foresite Labs with more than $1 billion in funding to develop AI technologies nurtured in the lab of co-founder David Baker, director of the UW Medicine Institute for Protein Design.
It is led by Marc Tessier-Lavigne, previously chief scientific officer at Genentech, with senior management that also includes co-founder Hetu Kamisetty – previously at Meta and former colleague of Baker at UW – as well as ex-Genentech executives...
Today's Sponsors
Today's Sponsor